Drug Profile
Research programme: neurodegenerative disease therapeutics - Takeda/University College London
Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Takeda; University College London
- Class
- Mechanism of Action Genetic process modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for research development in Neurodegenerative-disorders in United Kingdom
- 13 Oct 2015 Early research in Neurodegenerative disorders in United Kingdom (unspecified route)